Abstracts

MARAVIROC SAFETY & PHARMACOKINETICS IN HIV-EXPOSED NEONATES

Lack of adequate safety and pharmacokinetic (PK) data limits antiretroviral (ARV) prophylaxis and treatment options in HIV-exposed neonates. Maraviroc (MVC), a CCR5 receptor antagonist approved for use in adults, has potential for use in prophylaxis and treatment of HIV-exposed or infected neonates. IMPAACT 2007 is an ongoing Phase I, multi-center, open-label study of MVC safety…

LONGITUDINAL STUDY OF NEUROCOGNITIVE DISORDERS AND BRAIN STRUCTURE IN ADOLESCENT HIV

Neurocognitive disorders (NCD) despite ART are well known in perinatally-infected HIV+ adolescents (PHIV) but there are few data on longitudinal changes in NCD and brain structure in PHIV over time.  Within this sub-study of the Cape Town Adolescent Antiretroviral Cohort, PHIV on ART >6m completed baseline and 3-year follow-up assessments including a comprehensive neurocognitive battery assessing…

IDENTIFICATION OF AGE-APPROPRIATE DOSING STRATEGIES OF BICTEGRAVIR IN NEONATES

Paediatric patients differ from older patients in terms of drug metabolism and disposition, which necessitates evaluation of age-appropriate dosing strategies. Historically, this has complicated drug development resulting in fewer treatment options for neonates. PBPK modelling can be employed in early drug development to help inform selection of appropriate medicines at appropriate doses for paediatric patients.…

BRAIN DEVELOPMENT IN TREATED PERINATAL HIV: A LONGITUDINAL NEUROIMAGING STUDY

Cross-sectional studies, including our NOVICE study (Neurological Visual and Cognitive performance in treated perinatally HIV-infected [PHIV] children compared to age-, sex-, ethnicity- and socioeconomic status [SES]-matched HIV-uninfected controls), have reported lower white matter (WM) and grey matter (GM) volumes, higher WM hyperintensity (WMH) volume and poorer WM integrity measures in treated PHIV children. It is…

VIRAL SUPPRESSION AND MARIJUANA MODULATE TRANSCRIPTOME BIOPROFILE IN YOUTH WITH HIV

Viral suppression by antiretroviral therapy (ART) modulates many inflammatory pathways perturbed by HIV, but does not completely normalize inflammation. Substance use, particularly marijuana, affects pro-inflammatory pathways. A systems biology approach was used to define the transcriptome profiles associated with viral suppression and marijuana use in youth with HIV (YWH). The study included 20 YWH with…

PROMISING RESULTS FROM A PILOT RCT MENTAL HEALTH INTERVENTION FOR HIV-INFECTED YOUTH

There are increasing numbers of youth living with HIV (YLWH) with unaddressed mental health challenges. Mental health challenges are associated with poor antiretroviral therapy (ART) adherence which lead to unacceptably high mortality. Few evidence-based mental health interventions exist to address mental health challenges and improve HIV outcomes specifically for YLWH. This pilot group treatment trial,…

SUBSTANCE USE IN PERINATALLY INFECTED AND SAME-AGE HIV– ADOLESCENTS IN SOUTH AFRICA

Experimentation with substances is common among adolescents, but there are few longitudinal data exploring the prevalence among perinatally-infected adolescents living with HIV (PHIV+) in sub-Saharan Africa, including comparisons with HIV- adolescents. The Cape Town Adolescent Antiretroviral Cohort follows PHIV+ and age- and gender-matched HIV- adolescents in South Africa. Self-reported substance use was assessed annually, and…